Fact summary available from links:
1) Target market is large. A person dies from CVDs every 38 seconds, more than from all oncology, cancer-related causes combined. Vascepa is directed toward providing a major advance in solving that problem by reducing that risk.
2) A sNDA is before the FDA, filed in late March 2019. A FDA AdCom was convened 11/14/2019; it recommended approval of an expanded label for Vascepa, 16-0. FDA’s pdufa date is on or before 12/28/2019. Major trade organizations/entities including ADA, AHA, ACC, NLA, Mayo Clinic echo that request for approval of an expanded label for Vascepa, adding Vascepa to the recommended SOCs of each.
3) Vascepa is currently priced far lower than other medications. Vascepa has not been the subject of price reductions emanating from any political party.
4) Prescriptions for Vascepa have obtained all-time highs in market share, necessarily from off-label scrips from the current niche label indication. I have had an off-label scrip for Vascepa since April 2013. With insurance and company card, I pay $36 out of pocket cost per year( $9 for a 3 month refill of that prescription).
5) I try to provide information from which other investors can invest or not. The decision to invest is up to each individual. I make no recommendations. Current share price targets range from $30 to over $50 per share. The basis for our shares is ~ $2.78. We hold > 100k shares.
News 
Market Data 
Discover 
